Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Centre Francois Baclesse
NRG Oncology
Sun Yat-sen University
All India Institute of Medical Sciences, Jodhpur
Covenant Health Cancer Center
Johannes Gutenberg University Mainz
M.D. Anderson Cancer Center
Groupe Oncologie Radiotherapie Tete et Cou
Dow University of Health Sciences
Cairo University
Gustave Roussy, Cancer Campus, Grand Paris
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
University of British Columbia
Groupe Oncologie Radiotherapie Tete et Cou
Tata Memorial Hospital
Tata Memorial Hospital